1. Search Result
Search Result
Results for "

HUVECs

" in MedChemExpress (MCE) Product Catalog:

201

Inhibitors & Agonists

1

Fluorescent Dye

2

Biochemical Assay Reagents

16

Peptides

2

MCE Kits

3

Inhibitory Antibodies

48

Natural
Products

3

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N8248

    (+)-Eleutherin

    Topoisomerase Cardiovascular Disease
    Eleutherin is a type of naphthoquinone derivative with the protective effect against the injury ofhuman umbilical vein endothelial cells (HUVECs), which can be isolated from the edible bulbs of Eleutherine americana (Hong-Cong) .
    Eleutherin
  • HY-160259

    PROTACs VEGFR Cardiovascular Disease
    VEGFR-2-IN-39 (PROTAC-5) is a PROTAC targeting VEGFR-2 (IC50: 208.6 nM). VEGFR-2-IN-39 has low toxicity.VEGFR-2-IN-39 inhibits the proliferation of EA.hy926, one of HUVECs, in a concentration-dependent manner, with an IC50 of 38.65 µM .
    VEGFR-2-IN-39
  • HY-155174

    Akt Cancer
    Antiangiogenic agent 4 (Compound 3b) inhibits Akt phosphorylation in HFF and HUVEC cells. Antiangiogenic agent 4 can be used for cancer research .
    Antiangiogenic agent 4
  • HY-164551

    VEGFR STAT ERK Apoptosis Cancer
    YLL545 is a type of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC). YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth .
    YLL545
  • HY-151996

    Microtubule/Tubulin Cardiovascular Disease
    Tubulin inhibitor 31 is a potent tubulin inhibitor with an IC50 value of 4 µM. Tubulin inhibitor 31 shows anti-proliferative activity. Tubulin inhibitor 31 inhibits the HUVEC migration .
    Tubulin inhibitor 31
  • HY-163881

    VEGFR Cancer
    VEGFR-IN-5 (compound 9k) is a potent inhibitor of VEGFR2, with the IC50 of 8.4 nM and an acceptable oral bioavailability. VEGFR-IN-5 inhibits migration and invasion of human umbilical vein endothelial cells (HUVEC) cells and induces apoptosis .
    VEGFR-IN-5
  • HY-147891

    Apoptosis Cancer
    Angiogenesis inhibitor 3 (compound 8) is a potent angiogenesis inhibitor. Angiogenesis inhibitor 3 inhibits the proliferation of HUVEC and HCT-15 cells, with IC50 values of 1.00 and 0.71 μM. Angiogenesis inhibitor 3 induces the apoptosis of HUVEC and HCT-15 cells. Angiogenesis inhibitor 3 shows anticancer activity, and suppresses the invasion of cancer cells. Angiogenesis inhibitor 3 inhibits the angiogenesis in zebrafish embryos .
    Angiogenesis inhibitor 3
  • HY-147890

    Apoptosis Cancer
    Angiogenesis inhibitor 2 (compound 72) is a potent angiogenesis inhibitor. Angiogenesis inhibitor 2 inhibits the proliferation of HUVEC and HCT-15 cells, with IC50 values of 1.93 and 0.21 μM. Angiogenesis inhibitor 2 induces the apoptosis of HUVEC and HCT-15 cells. Angiogenesis inhibitor 2 shows anticancer activity, and suppresses the invasion of cancer cells. Angiogenesis inhibitor 2 inhibits the angiogenesis in zebrafish embryos .
    Angiogenesis inhibitor 2
  • HY-135216

    Src VEGFR Raf EGFR Cancer
    Antiproliferative agent-54 (Compound 6z) is the inhibitor for multiple kinases, such as ABL WT, B-RAF, EGFR, HCK, LYN A and SRC with IC50 of 6-50 nM. Antiproliferative agent-54 inhibits proliferation of several cancer cell, inhibits HUVEC and HepG2, with EC50 of 34 and 38 nM. Antiproliferative agent-54 exhibits good pharmacokinetic characteristics in rats .
    Antiproliferative agent-54
  • HY-101015

    Phospholipase Apoptosis Inflammation/Immunology
    (2E)-OBAA is a potent phospholipase A2 (PLA2) inhibitor, with an IC50 of 70 nM. (2E)-OBAA induces apoptosis of HUVEC cells. (2E)-OBAA blocks Melittin-induced Ca 2+ influx in Trypanosoma brucei, with an IC50 of 0.4 μM .
    (2E)-OBAA
  • HY-N2927

    β-Costic acid

    Parasite Infection
    Costic acid (β-Costic acid) is a natural product, that can be isolated from Dittrichia viscosa. Costic acid exhibits potent in vivo acaricidal activity against the parasite. Costic acid is not toxic for human umbilical vein endothelial cells (HUVEC) at concentrations of up to 230 μM. Costic acid can be used for the research of varroosis in honey bee colonies .
    Costic acid
  • HY-W009749C

    Endogenous Metabolite Apoptosis Cardiovascular Disease
    L-Cystathionine (dihydrochloride) is a nonprotein thioether and is a key amino acid associated with the metabolic state of sulfur-containing amino acids. L-Cystathionine (dihydrochloride) protects against Homocysteine-induced mitochondria-dependent apoptosis of vascular endothelial cells (HUVECs). L-Cystathionine (dihydrochloride) plays an important role in cardiovascular protection .
    L-Cystathionine dihydrochloride
  • HY-158006

    MetAP Cancer
    SDX-7539 is a selective inhibitor for Methionine aminopeptidase type 2 (MetAP2). SDX-7539 inhibits proliferarion of HUVECs with an IC50 of 120 μM. SDX-7539 exhibits antitumor activity in NSCLC xenograft athymic nude mice .
    SDX-7539
  • HY-115436

    Apoptosis Cancer
    LYG-202, a flavonoid, has potent anti-angiogenic and antitumor activity. LYG-202 inhibits VEGF-stimulated HUVEC migration and tube formation. LYG-202 induces cancer cell apoptosis .
    LYG-202
  • HY-118622

    Others Others
    Isogentisin is a cell protector. Isogentisin can shield human umbilical vein endothelial cells (HUVEC) from cell death caused by H202 and UV exposure. Isogentisin can also prevent endothelial damage triggered by smoking by activating cell repair functions to promote cell survival .
    Isogentisin
  • HY-P5877

    PKC Inflammation/Immunology
    PKC(85–92),Myristoylated is a cell permeable myristic acid conjugated PKC peptide activator that enhances NO release in cultured human umbilical vein endothelial cells (HUVECs) .
    ɛPKC(85–92),Myristoylated
  • HY-161313

    Histone Methyltransferase HIF/HIF Prolyl-Hydroxylase Cancer
    DYB-03 is an oral active HIF-1α/EZH2 inhibitor. DYB-03 inhibits migration, invasion, and angiogenesis of lung cancer cells and HUVECs in vitro and in vivo. DYB-03 induces apoptosis in 2-ME2 - and GSK126 -resistant of A549 and H460 cells .
    DYB-03
  • HY-162601

    Histone Methyltransferase HIF/HIF Prolyl-Hydroxylase Cancer
    D-01 is a dual-targeting inhibitor of HIF-1α and EZH2 (IC50: 4.86 μM and 0.99 μM respectively). D-01 inhibits the expression of H3K27me3 protein. D-01 inhibits the migration, clone and the invasion of A549 cells, and also inhibits tube formation of HUVECs. D-01 can be used for research of lung cancer .
    D-01
  • HY-161836

    Adrenergic Receptor Cardiovascular Disease
    α2AR agonist 1 (compound S6a), a new morpholine-containing pyrimidinone, acts as an agonist of α2-adrenoceptor. α2AR agonist 1 induces a concentration-dependent relaxation on aortic ring pre-contracted with Phenylephrine (HY-B0769; pEC50=6.81). α2AR agonist 1 increases NOx and NO levels in HUVECs .
    α2AR agonist 1
  • HY-W009749

    Endogenous Metabolite Apoptosis Cardiovascular Disease
    L-Cystathionine is a nonprotein thioether and is a key amino acid associated with the metabolic state of sulfur-containing amino acids. L-Cystathionine protects against Homocysteine-induced mitochondria-dependent apoptosis of vascular endothelial cells (HUVECs). L-Cystathionine plays an important role in cardiovascular protection .
    L-Cystathionine
  • HY-13645

    VEGFR c-Kit PDGFR Cancer
    Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib inhibits the activity of VEGFR-2, c-kit, PDGFR with IC50 values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway in human umbilical vein endothelial cells (HUVECs) .
    Henatinib
  • HY-126010
    Dooku1
    5+ Cited Publications

    Piezo Channel Others
    Dooku1 is a reversibly Yoda1 antagonist with IC50 value of 1.3 μM and 1.5 μM for 2 μM Yoda1-induced Ca 2+ entry HEK 293 cells and HUVECs, respectively. Dooku1 can disrupt Yoda1-induced Piezo1 channel activity and inhibit Yoda1-induced relaxation of aorta. Dooku1 can be used for vascular physiology and disease research .
    Dooku1
  • HY-125919

    Reactive Oxygen Species Bacterial Endogenous Metabolite Infection Inflammation/Immunology
    Vulpinic acid, a lichen metabolite, decreases H2O2-induced ROS production, oxidative stress and oxidative stress-related damages in human umbilical vein endothelial cells (HUVEC). Vulpinic acid is active against staphylococci, enterococci, and anaerobic bacteria.Vulpinic acid has the potential for atherosclerosis research .
    Vulpinic acid
  • HY-147949

    Microtubule/Tubulin Apoptosis Cancer
    SKLB0565 is a potent tubulin inhibitor. SKLB0565 shows significant anti-proliferative activity against CRC (colorectal carcinoma) cell lines, with IC50 values ranging from 0.012 μM to 0.081 μM. SKLB0565 causes G2/M phase arrest and mitochondria-mediated intrinsic apoptosis. SKLB0565 inhibits cell migration and disrupted the tube formation of HUVECs .
    SKLB0565
  • HY-18318

    Raf VEGFR PERK Cancer
    Takeda-6D (compound 6d) is an orally active and potent BRAF/VEGFR2 inhibitor, with IC50 values of 7.0 and 2.2 nM, respectively. Takeda-6D shows antiangiogenesis by suppressing the VEGFR2 pathway in 293/KDR and VEGF-stimulated HUVEC cells.Takeda-6D shows significant suppression of ERK1/2 phosphorylation. Takeda-6D shows antitumor activity .
    Takeda-6D
  • HY-144659

    Beta-lactamase Apoptosis Bacterial Infection
    Metallo-β-lactamase-IN-5 (compound 5c) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-5 shows inhibitory activity against MBLs NDM-1 and VIM-1. Metallo-β-lactamase-IN-5 inhibits HUVECs with an IC50 of 45 μg/mL. Metallo-β-lactamase-IN-5 plus Imipenem exhibits synergistic antimicrobial activity .
    Metallo-β-lactamase-IN-5
  • HY-P3418

    CCR ERK Inflammation/Immunology
    CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research .
    CKLF1-C27
  • HY-P3418A

    CCR ERK Inflammation/Immunology
    CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research .
    CKLF1-C27 TFA
  • HY-115831

    S1P1 agonist 3

    LPL Receptor Cardiovascular Disease
    SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC50s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome .
    SAR247799
  • HY-B0987
    Ascorbyl palmitate
    3 Publications Verification

    L-Ascorbic acid 6-hexadecanoate; 6-O-Palmitoyl-L-ascorbic acid

    Reactive Oxygen Species Endogenous Metabolite Calcium Channel Sodium Channel Apoptosis NOD-like Receptor (NLR) Bcl-2 Family Caspase Inflammation/Immunology
    Ascorbyl palmitate is an orally active ester formed from ascorbic acid and palmitic acid, used as an antioxidant and food additive. Ascorbyl palmitate in preventing fat and oil oxidation is more efficient than Butylated hydroxyanisole (HY-B1066) and Butylated hydroxytoluene (HY-Y0172). Ascorbyl palmitate mitigates inhibition of collagen synthesis by select calcium and sodium channel blockers. Ascorbyl palmitate induces Apoptosis in human umbilical vein endothelial cells (HUVECs). Ascorbyl palmitate ameliorates inflammatory diseases by inhibition of NLRP3 inflammasome .
    Ascorbyl palmitate
  • HY-120200

    VEGFR Cardiovascular Disease Cancer
    YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research .
    YF-452
  • HY-149921

    Others Cancer
    Antiangiogenic agent 3 (compound 3) is a potent antiangiogenic agent. Antiangiogenic agent 3 is an inhibitor of human umbilical vein endothelial cells (HUVEC). Antiangiogenic agent 3 inhibits HUVEC migration and chemotactic motilities. Antiangiogenic agent 3 also decreases the gene expression of Src, cdc42, and MAPK .
    Antiangiogenic agent 3
  • HY-133924

    RQN-18690A

    Others Cardiovascular Disease Cancer
    18-Deoxyherboxidiene (RQN-18690A) is a potent angiogenesis inhibitor. 18-Deoxyherboxidiene targets SF3b, a spliceosome component that is a subcomplex of the U2 small nuclear ribonucleoprotein (snRNP) in the spliceosome. 18-Deoxyherboxidiene inhibits the migration and tube formation of human umbilical vein endothelial cells (HUVECs) without significant cell toxicity. 18-Deoxyherboxidiene has the potential for cancer research .
    18-Deoxyherboxidiene
  • HY-164530

    Src VEGFR Raf p38 MAPK Cancer
    SKLB646 is an orally active multi-target kinase inhibitor. SKLB646 shows significant inhibitory effects on SRC and VEGFR2 with IC50 values ??of 0.002 μmol/L and 0.012 μmol/L, respectively. SKLB646 also shows significant inhibitory effects on B-Raf and C-Raf with IC50 values ??of 0.022 μmol/L and 0.019 μmol/L, respectively. SKLB646 inhibits the activation of the SRC signaling pathway and blocks the MAPK signaling pathway by inhibiting Raf kinase. In addition, SKLB646 can inhibit the proliferation, migration and invasion of human umbilical vein endothelial cells (HUVEC) to inhibit tumor-induced angiopoietic formation. SKLB646 shows significant anti-proliferative and anti-survival activities against triple-negative breast cancer (TNBC) cell lines .
    SKLB646
  • HY-161863

    Microtubule/Tubulin Reactive Oxygen Species Apoptosis Cancer
    Tubulin polymerization-IN-67 (Compound 5h) is an inhibitor for tubulin polymerization on colchicine binding site with an IC50 of 2.92 μM. Tubulin polymerization-IN-67 inhibits the proliferation of cancer cells HT29, A549, U2OS, MG-63 and HeLa with IC50s of 0.12-4.13 μM. Tubulin polymerization-IN-67 arrests the cell cycle at G2/M phase, induces apoptosis in cell U2OS, inhibits the cell migration of A549. Tubulin polymerization-IN-67 reduces the mitochondrial membrane potential (MMP) and increase intracellular ROS, inhibits the angiogenesis in HUVECs. Tubulin polymerization-IN-67 exhibits antitumor efficacy in mice
    Tubulin polymerization-IN-67
  • HY-168127

    VEGFR Cancer
    VEGFR-2-IN-57 (compound 6n) exhibited significant cytotoxicity in HUVEC cells (IC50 = 28.77 nM).
    VEGFR-2-IN-57
  • HY-124918

    VEGFR Cancer
    Cremastranone is an antiangiogenic homoisoflavone. Cremastranone can inhibit HUVECs cell proliferation, with a GI50 value of 1.5 uM .
    Cremastranone
  • HY-103316

    Calcium Channel Cardiovascular Disease
    trans-Ned 19, a NAADP antagonist and TPC blocker, suppresses the calcium signal in human umbilical vein endothelial cells (HUVEC) and the rat aorta relaxation in response to low histamine concentrations .
    trans-Ned 19
  • HY-P5888

    Myr‐PKCɛ-

    PKC Inflammation/Immunology
    PKCε inhibitor peptide,myristoylated (Myr‐PKC -) is a cell permeable myristic acid conjugated PKC peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .
    PKCε inhibitor peptide,myristoylated
  • HY-N4020

    Others Others
    Icariside E5 is a lignan glycoside isolated from the Capsicum annuum. Icariside E5 promotes the proliferation of HUVECs without cytotoxicity. Icariside E5 has antioxidant properties .
    Icariside E5
  • HY-112353

    Endogenous Metabolite Others
    NP603 is a potent inhibitor of FGF receptor 1, exhibiting remarkable activity against endothelial proliferation in HUVEC cells stimulated by rhFGF-2, with a minimum effective dose of 0.4 microM.
    NP603
  • HY-N6737

    Bacterial Antibiotic Infection
    Aureothricin is a dithiolopyrrolone (DTP) antibiotic first isolated from Streptomyces and exhibits relatively broad-spectrum antibiotic activity. Aureothricin can inhibit adhesion of human umbilical vein endothelial cells (HUVECs) to vitronectin .
    Aureothricin
  • HY-P10860

    Factor Xa Cardiovascular Disease
    cMCoFx1 is a potent and selective FXIIa cyclic peptide inhibitor. cMCoFx1 has high binding affinity (KD: 900 pM) and inhibitory activity (Ki: 370 pM) for FXIIa. cMCoFx1 can effectively inhibit endogenous clotting pathways, and cMCoFx1 is stable in serum and non-cytotoxic .
    cMCoFx1
  • HY-136829

    Apoptosis Others
    BPH-675 is a large bisphosphonate inhibitor with long hydrophobic side chains and a potent and selective geranylgeranyl diphosphate synthase (GGPPS) inhibitor with an IC50 of 0.71 μM. GGPPS inhibitor promotes HUVEC apoptosis .
    BPH-675
  • HY-121356
    Carebastine
    1 Publications Verification

    Macrophage migration inhibitory factor (MIF) Histamine Receptor Endocrinology Cancer
    Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner . Carebastine suppresses the expression of macrophage migration inhibitory factor .
    Carebastine
  • HY-161330

    Bacterial Infection
    Anti-MRSA agent 10 (Compound 2d) is a Cephalosporin (HY-144229) derivative and exhibits antibacterial activity. Anti-MRSA agent 10 is slightly drug resistane and exhibits low cytotoxicity in cells HUVEC and HBZY-1 .
    Anti-MRSA agent 10
  • HY-W800162

    VEGFR Cancer
    VEGFR-2-IN-37 (compound 12) is an inhibitor of VEGFR-2. The inhibition rate at 200 μM was approximately 56.9 μM. VEGFR-2-IN-37 is a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation .
    VEGFR-2-IN-37
  • HY-W588250

    Integrin Inflammation/Immunology
    Surfactin C1 is an amphiphilic biosurfactants. Surfactin C1 inhibits leukemic cell (HL-60) adhesion to human umbilical vein endothelial cells (HUVEC). Surfactin C1 inhibits adhesion melecules expression, such as ICAM-1 and VCAM-1 .
    Surfactin C1
  • HY-121356S1

    Isotope-Labeled Compounds Histamine Receptor Endocrinology Cancer
    Carebastine-d5 Methyl Ester is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner[1]. Carebastine suppresses the expression of macrophage migration inhibitory factor[2].
    Carebastine-d5 Methyl Ester
  • HY-121356S

    Isotope-Labeled Compounds Histamine Receptor Endocrinology Cancer
    Carebastine-d5 is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner[1]. Carebastine suppresses the expression of macrophage migration inhibitory factor[2].
    Carebastine-d5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: